AstraZeneca
Pharmaceutical & Health Products · Lobbying Client
C
Influence Score
53/100
Moderate Influence
$19.4M
Total Lobby Spend
5
Policy Issues
8
Lobbyists
1
Revolving Door
AstraZeneca reported $19.4 million in federal lobbying expenditures as disclosed in Senate LDA filings. The organization's lobbying activity spans 5 policy areas, with primary focus on Health Issues, Pharmacy, Medical/Disease Research. This data is drawn from quarterly disclosure reports filed with the Secretary of the Senate under the Lobbying Disclosure Act of 1995.
Annual Lobbying Spend
Policy Issues
Government Entities Contacted
Food & Drug Administration
Dept of Health & Human Services
Dept of Treasury
US Trade Representative
US Senate
Dept of Homeland Security
Small Business Administration
Dept of Energy
Recent Filings
| Period | Registrant | Issues | Lobbyists | Amount |
|---|---|---|---|---|
| 2020 Jan-Mar | Squire Patton Boggs LLP | MED | 2 | $874K |
| 2020 Apr-Jun | Cassidy & Associates LLP | HCRPHAMED+1 | 4 | $1.0M |
| 2020 Jul-Sep | Akin Gump LLP | PHATAX | 3 | $1.2M |
| 2020 Oct-Dec | Akin Gump LLP | TAXPHAHCR+1 | 4 | $1.1M |
| 2021 Jan-Mar | K&L Gates LLP | HCR | 4 | $1.1M |
| 2021 Apr-Jun | Squire Patton Boggs LLP | PHAHCRGOV | 1 | $894K |
| 2021 Jul-Sep | Holland & Knight LLP | MEDPHAHCR+2 | 4 | $1.0M |
| 2021 Oct-Dec | K&L Gates LLP | HCRGOVPHA | 3 | $1.3M |